VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly-owned US subsidiary, Invictus Nutraceuticals, Inc. (IVN), has executed a Sales Representative Agreement with Continuum Sciences LLC of Colorado.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, will be presenting two abstracts at the American Physiological Society's (APS) Annual Meeting Experimental Biology Conference 2022 in Philadelphia, USA.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has executed a non-binding Term Sheet for the sale of its wholly owned subsidiary, the Invictus BioPharma Pty Ltd Group to Invictus BioPharma Holdings Ltd.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly-owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from a Lead Ethics Committee Site, Bellberry Ltd, for a Phase II clinical study on Non-Alcoholic Fatty Liver Disease.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that the Hong Kong Patent Office has granted a patent for the Transmucosal Delivery of Tocotrienols to its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd.
Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to provide shareholders and investors with an overview of activities for the period ending 31 December 2021.
Invictus Ops Pty Ltd, a wholly owned subsidiary of NSX-listed VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has contracted Resonance Health Ltd (ASX:RHT) to provide liver-fat quantification services for its clinical study on a potential new treatment for Non-Alcoholic Steatohepatitis.
